Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077437 | 0.92 | EGFR (0.51) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL6486733 | 0.92 | EGFR (0.51) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL6175165 | 0.90 | EGFR (0.55) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL4619108 | 0.90 | ERBB2 (0.55) | EGFRERBB2ERBB4ERBB3 | |
| SCHEMBL6175157 | 0.90 | EGFR (0.53) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL6487993 | 0.89 | EGFR (0.51) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL6176991 | 0.89 | EGFR (0.51) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL6189113 | 0.88 | ERBB2 (0.51) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL6175138 | 0.88 | ERBB2 (0.49) | EGFRERBB2FLT1EPHA2KDR | |
| SCHEMBL5077429 | 0.87 | EGFR (0.58) | EGFRERBB2FLT1EPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | disclosed |